Results 61 to 70 of about 2,230,889 (288)
In-hospital mortality of hepatorenal syndrome in the United States: Nationwide inpatient sample
World Journal of Gastroenterology, 2021 BACKGROUND Hepatorenal syndrome (HRS) is a life-threatening condition among patients with advanced liver disease. Data trends specific to hospital mortality and hospital admission resource utilization for HRS remain limited.
W. Kaewput +15 more
semanticscholar +1 more source
International Journal of Nephrology, 2015 Background/Aims. Acute kidney injury is a common problem for patients with cirrhosis and is associated with poor survival. We aimed to examine the association between type of acute kidney injury and 90-day mortality. Methods.
Andrew S. Allegretti +9 more
doaj +1 more source
Liver transplantation, 2021 Vasoconstrictors are the treatment of choice for hepatorenal syndrome (HRS). We evaluate the real‐life effectiveness of a sequential vasoconstrictor regimen of midodrine–octreotide followed by norepinephrine in a nonintensive care unit (non‐ICU) setting ...
A. Kwong +4 more
semanticscholar +1 more source
A rare and threatening complication in a cirrhotic patient [PDF]
, 2018 info:eu-repo/semantics ...
Anapaz, V, Branco, J, Reis, J, Santos, L
core +1 more source
Terlipressin effect on hepatorenal syndrome: Updated meta‐analysis of randomized controlled trials
JGH Open, 2021 Hepatorenal syndrome (HRS) is a fatal complication of liver cirrhosis with a limited pharmacological option. Terlipressin is a vasoconstrictor that is approved in many countries but not yet in the United States.
Mohamed M. G. Mohamed +5 more
semanticscholar +1 more source
Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1 [PDF]
, 2017 Background Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis.
Alessandria +34 more
core +2 more sources
Recent advances in the understanding and management of hepatorenal syndrome
Faculty Reviews, 2021 Renal dysfunction occurs frequently in hospitalized patients with advanced chronic liver disease (ACLD)/cirrhosis and has profound prognostic implications.
B. Simbrunner +3 more
semanticscholar +1 more source
It is reasonable to treat patients with type 1 hepatorenal syndrome with midodrine and octreotide [PDF]
, 2016 A critical appraisal and clinical application of Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA. Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;
Kane, William
core +2 more sources
Hepatorenal syndrome: Current concepts related to diagnosis and management
Annals of Hepatology, 2016 Renal failure in cirrhotic patients is a very severe condition. Hepatorenal syndrome has the worst prognosis among all causes of kidney failure in such patients.
Ângelo Zambam de Mattos +2 more
doaj +1 more source
The course of type 1 hepato-renal syndrome post liver transplantation [PDF]
, 2005 Background. Hepato-renal syndrome (HRS) is a functional form of renal failure that occurs in patients with end-stage liver disease. Previously considered fatal without liver transplantation, treatment with vasoconstrictors and albumin has been ...
Marik, PE, Starzl, TE, Wood, K
core +1 more source